Stock 2616 CSTONE PHARMACEUTICALS
Add to a list
To use this feature you must be a member
Log inSign up

All News CStone Pharmaceuticals

Equities

2616

KYG2588M1006

Market Closed - Hong Kong S.E.
Other stock markets
 09:09:00 03/05/2024 BST 		5-day change 1st Jan Change
1.1 HKD +0.92% Intraday chart for CStone Pharmaceuticals +22.22% -51.54%
05-02 Non-Executive Director Increases Shareholding in CStone Pharma; Shares Surge 25% MT
04-29 Cstone Pharmaceuticals’ CEO Boosts Stakeholding MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Non-Executive Director Increases Shareholding in CStone Pharma; Shares Surge 25%
MT
Cstone Pharmaceuticals’ CEO Boosts Stakeholding
MT
Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5%
MT
CStone Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023
CI
China Accepts CStone Pharmaceuticals' Manufacturing Application for RET Inhibitor
MT
CStone Announces the Availability of RET Inhibitor GAVRETO® Manufacturing Localization Application by Center for Drug Evalence of China NMPA
CI
Cstone Pharmaceuticals Cancer Drug Gets Supplemental Biologics License Application Approved
MT
CStone Pharmaceuticals Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer
CI
CStone Pharmaceuticals Booted From Hong Kong Stock Connect; Shares Plunge 25%
MT
CStone sells to Servier its exclusive rights to TIBSOVO in Greater China and Singapore
AQ
CStone Pharmaceuticals Arm to Sell Ivosidenib Business for $50 Million
MT
The Servier Group agreed to acquire CStone Pharmaceuticals, Exclusive rights to TIBSOVO® in Greater China and Singapore from CStone Pharmaceuticals for $44 million.
CI
China Includes CStone's Gastrointestinal Stromal Tumor Treatment in National Reimbursement List; Shares Jump 6%
MT
CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma
AQ
China Approves CStone Pharma's Treatment for Esophageal Squamous Cell Carcinoma; Shares Soar 21%
MT
CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab as First-Line Treatment for Esophageal Squamous Cell Carcinoma
CI
3SBio Secures Exclusive License to CStone's Anti-Tumor Drug in China
MT
CStone Pharmaceuticals Announces Strategic Partnership and Exclusive Licensing Agreement with Shenyang Sunshine Pharmaceuticals Co., Ltd for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China
CI
CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3Sbio for Nofazinlimab (ANTI-PD-1 Antibody) in Mainland China
CI
CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2616 Stock
  4. News CStone Pharmaceuticals